Table 4.
Statin use and LDL-C control of the study population.
| Characteristics | Statin use | LDL-C <1.8 mmol/L | ||
|---|---|---|---|---|
| Treated patients | All patients | |||
| Sex# | Male | 345 (69.0) | 60 (17.4) | 75 (15.0) |
| Female | 68 (57.6) | 12 (17.6) | 20 (16.9) | |
| Age group (y)# | <65 | 227 (72.5) | 42 (18.5) | 46 (14.7) |
| ≥65 | 186 (61.0) | 30 (16.1) | 49 (16.1) | |
| Duration of CABG (y) | <5 | 160 (67.8) | 26 (16.3) | 33 (14.0) |
| 5–9 | 173 (65.0) | 34 (19.6) | 46 (17.3) | |
| ≥10 | 80 (69.0) | 12 (15.0) | 16 (13.8) | |
| Artery graft disease#§ | Yes | 87 (54.0) | 10 (11.5) | 12 (7.5) |
| No | 326 (71.3) | 62 (19.0) | 83 (18.2) | |
#
Significant difference in statin use between the two groups (p < 0.05);
§
Significant difference in LDL-C control between patients with or without artery graft disease.
LDL-C, low-density lipoprotein cholesterol; CABG, coronary artery bypass grafting.